Oncologic outcomes and rates of hepatotoxicity following stereotactic body radiotherapy for hepatocellular carcinoma

Abstract

Aim: Hepatocellular carcinoma (HCC) localized to the liver has various treatment options, including external beam radiotherapy (EBRT). Despite many prospective and retrospective reports showing excellent local control (LC) and favorable toxicity, EBRT has not been widely adopted in the first-line setting and this may be due to a perceived lack of evidence. This study aims to share a decade of experience with Stereotactic Body Radiotherapy (SBRT) for HCC, leveraging a homogenous treatment technique.

Methods: This retrospective study at a single institution included patients with HCC treated with SBRT, with a standardized treatment protocol. Freedom from local progression (FFLP), overall survival (OS), and rates of hepatotoxicity post-treatment using child-pugh (CP) and albumin-bilirubin (ALBI) scores were analyzed. A mixed-effects multivariable analysis (MVA) was also performed to assess various factors’ impact on outcomes.

Results: A total of 138 lesions in 106 patients were treated between 2009 and 2020. FFLP was 91% at one year and 86% at three years. OS was 80% and 46% at 1 and 3 years, respectively. Baseline liver function was a significant predictor of FFLP and OS on MVA. CP scores and ALBI grades were stable 3 months after treatment in ≥ 70% of patients.

Conclusion: SBRT provides excellent LC and low toxicity for HCC patients. While long-term survival remains challenging, treatment decisions should consider overall clinical status. Multidisciplinary review and forthcoming prospective trial results will further clarify radiotherapy’s role in HCC management.

Keywords

Radiation / SBRT / hepatocellular carcinoma / liver

References

[1] Forner A,Bruix J.Hepatocellular carcinoma.Lancet2018;391:1301-14

[2] Soliman H,Jiang H.Phase II trial of palliative radiotherapy for hepatocellular carcinoma and liver metastases.J Clin Oncol2013;31:3980-6

[3] Wong TC,Law AL.Prospective study of stereotactic body radiation therapy for hepatocellular carcinoma on waitlist for liver transplant.Hepatology2021;74:2580-94 PMCID:PMC9291538

[4] Mathew AS.Current understanding of ablative radiation therapy in hepatocellular carcinoma.J Hepatocell Carcinoma2021;8:575-86 PMCID:PMC8214025

[5] Murray LJ.Advances in stereotactic body radiation therapy for hepatocellular carcinoma.Semin. Radiat Oncol2017;27:247-55

[6] Reig M,Rimola J.BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update.J Hepatol2022;76:681-93 PMCID:PMC8866082

[7] Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma.J. Hepatol2018;69:182-236

[8] Rasic G,Papageorge MV.Disparities in the receipt of recommended curative treatment for patients with early-stage hepatocellular carcinoma.World J Surg2023;47:1780-89

[9] Hasan S,Jan I,Thai N.The albumin-bilirubin (ALBI) model in hepatocellular carcinoma (HCC) may better predict hepatic failure in patients with traditionally low-risk cirrhosis following definitive stereotactic body radiotherapy (SBRT).J Radiat Oncol2018;7, 247-53

[10] Su TS,Zhou Y.Albumin - bilirubin (ALBI) versus child-turcotte-pugh (CTP) in prognosis of HCC after stereotactic body radiation therapy.Radiat Oncol2019;14:50. PMCID:PMC6436219

[11] Moon DH,Tepper JE.A prospective study of the safety and efficacy of liver stereotactic body radiotherapy in patients with and without prior liver-directed therapy.Radiother Oncol2018;126:527-33

[12] Kielar A,Lewis S.Locoregional therapies for hepatocellular carcinoma and the new LI-RADS treatment response algorithm.Abdom Radiol (NY)2018;43:218-30 PMCID:PMC5771991

[13] Apisarnthanarax S,Cao M.External beam radiation therapy for primary liver cancers: an ASTRO clinical practice guideline.Pract Radiat Oncol2022;12:28-51

[14] Singal AG,Yarchoan M.AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma.Hepatology2023;78:1922-65 PMCID:PMC10663390

[15] Yanagihara TK,Moon AM.Defining minimum treatment parameters of ablative radiation therapy in patients with hepatocellular carcinoma: an expert consensus.Pract Radiat Oncol2024;14:134-45

[16] Moon AM,Singal AG.Thermal ablation compared to stereotactic body radiation therapy for hepatocellular carcinoma: a multicenter retrospective comparative study.Hepatol Commun2023;7:e00184 PMCID:PMC10270501

[17] Kimura T,Tsurugai Y.A multi-institutional retrospective study of repeated stereotactic body radiation therapy for intrahepatic recurrent hepatocellular carcinoma.Int J Radiat Oncol Biol Phys2020;108:1265-75

[18] Roquette I,Lacornerie T.Stereotactic body radiation therapy for the management of hepatocellular carcinoma: efficacy and safety.Cancers (Basel)2022;14:3892 PMCID:PMC9405555

[19] Hong TS,Yeap BY.Multi-institutional phase II study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma.J Clin Oncol2016;34:460-8 PMCID:PMC4872014

[20] Weiss J,Deal A.Progression-free survival, overall survival and immunophenotyping outcomes for patients with stage III-IV head and neck cancer and cisplatin contraindication treated with definitive radiotherapy plus pembrolizumab.Int J Radiat Oncol Biol Phys2020;106:1221

[21] Kim TH,Kim BH.Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: a randomized phase III trial..J Hepatol2021;74:603-12